Form 4: Seres Therapeutics Executive Acquires 650,000 Stock Options
SEC Form 4 Filing
Teresa L. Young, EVP, Chief Commercial & Strategy Officer of Seres Therapeutics, acquired 650,000 stock options on February 7, 2025.
Summary
- On February 7, 2025, Teresa L. Young, EVP, Chief Commercial & Strategy Officer of Seres Therapeutics, Inc. (MCRB), acquired 650,000 stock options.
- The options have an exercise price of $0.782.
- 25% of the options will vest on February 7, 2026, with the remainder vesting in 12 equal quarterly installments thereafter.
- The options expire on February 6, 2035.
Sentiment
Score: 5
Explanation: This is a routine filing related to executive compensation. It doesn't inherently indicate positive or negative sentiment, but rather reflects standard corporate governance practices.
Industry Context
This is a standard practice for incentivizing and retaining key executives in publicly traded companies. Stock options align the executive's interests with those of the shareholders.
Stakeholder Impact
- The granting of stock options to executives can align their interests with those of shareholders, potentially driving long-term value creation.
Key Dates
| Date | Description |
|---|---|
| 02/07/2025 | Date of transaction: Teresa L. Young acquired 650,000 stock options. |
| 02/07/2026 | 25% of the stock options vest. |
| 02/06/2035 | Expiration date of the stock options. |
| 02/11/2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.